The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 601–700 of 1,003
Pathophysiologic mechanisms of postprandial hyperglycemia
Gavin, J. R. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01830-6 · Cited by 46
Pathophysiology of diabetes mellitus type 2: beyond the duo "insulin resistance-secretion deficit".
Boada, C. A. C., & Martínez-Moreno, J. M. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6717 · Cited by 44
Claus, T. H., Pan, C. Q., Buxton, J. M., Yang, L., Reynolds, J. C., Barucci, N., Burns, M. G., Ortiz, A. A., Roczniak, S., Livingston, J. N., et al. (2007) · Journal of Endocrinology · doi:10.1677/joe-06-0018 · Cited by 46
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
Bidel, S., Hu, G., Sundvall, J., Kaprio, J. A., & Tuomilehto, J. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-924982 · Cited by 46
Gastro-intestinal hormones GIP and GLP-1
Kieffer, T. J. (2004) · Annales d Endocrinologie · doi:10.1016/s0003-4266(04)95625-9 · Cited by 46
Zander, M., Madsbad, S., Deacon, C. F., & Holst, J. J. (2005) · Diabetologia · doi:10.1007/s00125-005-0098-y · Cited by 45
Self-citationJohnson, K., Edgerton, D. S., Rodewald, T., Scott, M. F., Farmer, B., Neal, D. W., & Cherrington, A. D. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00275.2007 · Cited by 46
Intestinal effects of α‐glucosidase inhibitors: absorption of nutrients and enterohormonal changes
Göke, B., Herrmann, C. H., Göke, R., Fehmann, H. C., Berghöfer, P., Richter, G., & Arnold, R. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb02252.x · Cited by 46
Nauck, M. A., Walberg, J., Vethacke, A., El-Ouaghlidi, A., Senkal, M., Holst, J. J., Gallwitz, J. B., Schmidt, W. E., & Schmiegel, W. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.11.003 · Cited by 46
Self-citationMcLaughlin, C. M., Harnedy-Rothwell, P. A., Lafferty, R. A., Sharkey, S., Parthsarathy, V., Allsopp, P. J., McSorley, E. M., FitzGerald, R. J., & O’Harte, F. P. M. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02583-3 · Cited by 45
The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study
Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M. A., Rayner, C. K., & Jones, K. L. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05198.x · Cited by 46
Self-citationEffects of endogenous GIP in patients with type 2 diabetes
Stensen, S., Gasbjerg, L. S., Krogh, L. S. L., Skov‐Jeppesen, K., Sparre‐Ulrich, A. H., Jensen, M., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0135 · Cited by 46
Self-citationGlucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose
Zhang, Y., Han, C., Zhu, W., Yang, G., Peng, X., Mehta, S., Zhang, J., Chen, L., & Liu, Y. (2021) · Cells · doi:10.3390/cells10092495 · Cited by 47
Forst, T., Weber, M. M., & Pfützner, A. (2012) · Experimental Diabetes Research · doi:10.1155/2012/635472 · Cited by 44
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 47
Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
Neumiller, J. J., & Campbell, R. K. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090555 · Cited by 42
Is there a place for incretin therapies in obesity and prediabetes?
Holst, J. J., & Deacon, C. F. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.01.004 · Cited by 44
Self-citationRelationship between gut hormones and glucose homeostasis after bariatric surgery
Sala, P. C., Torrinhas, R. S., Giannella‐Neto, D., & Waitzberg, D. L. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-87 · Cited by 45
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 49
Markova, M., Hornemann, S., Sucher, S., Wegner, K., Pivovarova‐Ramich, O., Rudovich, N. N., Thomann, R., Schneeweiss, R., Rohn, S., & Pfeiffer, A. F. H. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy100 · Cited by 45
Kerr, B. D., Irwin, N., O'Harte, F. P. M., Bailey, C. J., Flatt, P. R., & Gault, V. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.037 · Cited by 44
O'Harte, F. P. M. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00214-7 · Cited by 44
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
Self-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citationReview of the Therapeutic Uses of Liraglutide
Ryan, G. J., Foster, K. T., & Johnson, L. M. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.004 · Cited by 42
GLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 43
Incretin secretion in humans is under the influence of cannabinoid receptors
Chia, C. W., Carlson, O. D., Liu, D. D., González‐Mariscal, I., Calvo, S. S.-C., & Egan, J. M. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00080.2017 · Cited by 43
Pathological Mechanisms in Diabetes of the Exocrine Pancreas: What’s Known and What’s to Know
Wei, Q., Qi, L., Lin, H., Liu, D., Zhu, X., Dai, Y., Waldron, R. T., Lugea, A., Goodarzi, M. O., Pandol, S. J., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.570276 · Cited by 49
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 48
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2021) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 50
Self-citationCitters, G. W. V., Kabir, M., Kim, S. P., Mittelman, S. D., Dea, M. K., Brubaker, P. L., & Bergman, R. N. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020002 · Cited by 44
β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity
Aulinger, B. A., Vahl, T. P., Wilson, H., Prigeon, R. L., & D’Alessio, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4009 · Cited by 44
The evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Nauck, M. A., Kahle, M., Baranov, O., Deacon, C. F., & Holst, J. J. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12802 · Cited by 44
Self-citationGasbjerg, L. S., ROSENKILDE, M. M., Meier, J. J., Holst, J. J., & Knop, F. K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15216 · Cited by 43
Self-citationAbdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 45
KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state
Ogata, H., Seino, Y., Harada, N., Iida, A., Suzuki, K., Izumoto, T., Ishikawa, K., Uenishi, E., Ozaki, N., Hayashi, Y., et al. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0161 · Cited by 44
Diabetic Gastroparesis and Its Impact on Glycemia
Chang, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.08.007 · Cited by 43
Ramesh, N., Mortazavi, S., & Unniappan, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.100 · Cited by 41
Medicinal Chemistry of Incretin Mimetics and DPP‐4 Inhibitors
Zettl, H., Schubert‐Zsilavecz, M., & Steinhilber, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900448 · Cited by 42
Signal Transduction of PACAP and GLP-1 in Pancreatic β Cellsa
Leech, C. A., Holz, G. G., & Habener, J. F. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17475.x · Cited by 42
Functional importance of GLP-1 receptor species and expression levels in cell lines
Knudsen, L. B., Hastrup, S., Underwood, C. R., Wulff, B. S., & Fleckner, J. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2011.12.006 · Cited by 41
Enteroendocrine hormone mimetics for the treatment of obesity and diabetes
Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41
DPP IV inhibitors: Successes, failures and future prospects
Kshirsagar, A. D., Aggarwal, A. S., Harle, U. N., & Deshpande, A. D. (2011) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2012.02.017 · Cited by 41
Irwin, N., McClean, P. L., Patterson, S., Hunter, K., & Flatt, P. R. (2008) · Biological Chemistry · doi:10.1515/bc.2009.002 · Cited by 38
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 43
Kong, M., King, P., Macdonald, I. A., Blackshaw, P. E., Horowitz, M., Perkins, A. C., Armstrong, E., Buchanan, K. D., & Tattersall, R. B. (1999) · Diabetologia · doi:10.1007/s001250051164 · Cited by 40
Gallwitz, B., Witt, M., Morys‐Wortmann, C., Fölsch, U. R., & Schmidt, W. E. (1996) · Regulatory Peptides · doi:10.1016/0167-0115(96)00019-5 · Cited by 41
The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update
Lyssenko, V. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328304d970 · Cited by 41
Irwin, N., Gault, V. A., Green, B. D., Greer, B., Harriott, P., Bailey, C. J., Flatt, P. R., & O'Harte, F. P. M. (2005) · Biological Chemistry · doi:10.1515/bc.2005.079 · Cited by 41
Update on cystic fibrosis-related diabetes
Stecenko, A. A., & Moran, A. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32833e8700 · Cited by 43
Mizuno, A., Noma, Y., Kuwajima, M., Murakami, T., Zhu, M., & Shima, K. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90107-5 · Cited by 41
Irwin, N., Green, B. D., Gault, V. A., Greer, B., Harriott, P., Bailey, C. J., Flatt, P. R., & O'Harte, F. P. M. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049262s · Cited by 41
Meier, J. J., Nauck, M. A., Siepmann, N., Greulich, M., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Gallwitz, B. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00327-5 · Cited by 41
Self-citationGut mechanisms linking intestinal sweet sensing to glycemic control
Kreuch, D., Keating, D. J., Wu, T., Horowitz, M., Rayner, C. K., & Young, R. L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00741 · Cited by 40
“GLP-1 andGIP, the “íncretin” peptide hormones, are degraded rapidly upon release by the ubiquitous enzyme dipeptidyl peptidase-IV and neutral endopeptidase, with 50% of secreted hormone entering the circulation.”
BackgroundInfluentialLupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 41
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 44
Diabetic gastroparesis—Backwards and forwards
Chang, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06573.x · Cited by 40
Bahekar, R. H., Jain, M. R., Gupta, A. A., Goel, A., Jadav, P., Patel, D. N., Prajapati, V. M., & Patel, P. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200700024 · Cited by 40
Furuta, S., Smart, C., Hackett, A., Benning, R. K., & Warrington, S. (2012) · Xenobiotica · doi:10.3109/00498254.2012.731618 · Cited by 40
Talbot, J., Joly, E. C., Prentki, M., & Buteau, J. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.010 · Cited by 40
The incretin effect in K orean subjects with normal glucose tolerance or type 2 diabetes
Oh, T. J., Kim, M. Y., Shin, J. Y., Lee, J. C., Kim, S., Park, K. S., & Cho, Y. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12167 · Cited by 41
Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers
He, Y., Sabo, R., Sunkara, G., Bizot, M., Rivière, G., Leon, S., Ligueros‐Saylan, M., Dole, W. P., & Howard, D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007301802 · Cited by 40
Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 40
Self-citationSuzuki, K., Iwasaki, K., Murata, Y., Harada, N., Yamane, S., Hamasaki, A., Shibue, K., Joo, E., Sankoda, A., Fujiwara, Y., et al. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12681 · Cited by 42
Purnell, J. Q., Johnson, G., Wahed, A. S., Man, C. D., Piccinini, F., Cobelli, C., Prigeon, R. L., Goodpaster, B. H., Kelley, D. E., Staten, M. A., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4553-y · Cited by 41
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Riche, D. M., East, H. E., & Riche, K. D. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818eb721 · Cited by 40
Salapatek, A. M., MacDonald, P. E., Gaisano, H. Y., & Wheeler, M. B. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.8.0321 · Cited by 40
Irwin, N., Clarke, G. C., Green, B. D., Greer, B., Harriott, P., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.06.013 · Cited by 40
Santoro, S., Velhote, M. C. P., Malzoni, C. E., Milleo, F. Q., Klajner, S., & Campos, F. G. (2006) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802006000400004 · Cited by 40
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
Yamane, S., Harada, N., Hamasaki, A., Muraoka, A., Joo, E., Suzuki, K., Nasteska, D., Tanaka, D., Ogura, M., Harashima, S., et al. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00143.x · Cited by 39
Endocrine and metabolic response to gastric bypass
Saliba, J., Wattacheril, J. J., & Abumrad, N. N. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832e1b14 · Cited by 40
The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors
Morales, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.11.2508 · Cited by 41
The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats
Gilor, C., Graves, T. K., Gilor, S., Ridge, T. K., & Rick, M. (2011) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2011.03.001 · Cited by 39
Jun, H., Bae, H. Y., Lee, B. R., Koh, K. S., Kim, Y., Lee, K. W., Kim, H., & Yoon, J. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00071-4 · Cited by 40
Mining incretin hormone pathways for novel therapies
Wideman, R. D., & Kieffer, T. J. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.02.005 · Cited by 39
Yu, Y.-W., Hsieh, T.-H., Chen, K., Wu, J. C.-C., Hoffer, B. J., Greig, N. H., Li, Y., Lai, J.-H., Chang, C., Lin, J., et al. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4229 · Cited by 39
Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice
Mori, Y., Kushima, H., Koshibu, M., Saito, T., Hiromura, M., Kohashi, K., Terasaki, M., Seino, Y., Yamada, Y., & Hirano, T. (2018) · Endocrinology · doi:10.1210/en.2018-00336 · Cited by 41
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
Gray, S. M., Xin, Y., Ross, E. C., Chazotte, B. M., Capozzi, M. E., EL, K. M., Svendsen, B., Ravn, P., Sloop, K. W., Tong, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014368 · Cited by 41
Chueire, V. B., & Muscelli, E. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000313 · Cited by 41
Kim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 41
Irwin, N., Hunter, K., Frizzell, N., & Flatt, P. R. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.11.007 · Cited by 38
Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects
DeLeon, M. J., Chandurkar, V., Albert, S. G., & Mooradian, A. D. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00359-x · Cited by 39
Campbell, R. K. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h459 · Cited by 39
Sinclair, E. M., & Drucker, D. J. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000155379.11926.e2 · Cited by 39
7 Humoral regulation of intestinal adaptation
Taylor, R. G., & Fuller, P. J. (1994) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80230-7 · Cited by 38
Permana, H., Yanto, T. A., & Hariyanto, T. I. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102640 · Cited by 38
Harnessing molecular recognition for localized drug delivery
Liu, R., Zuo, R., & Hudalla, G. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.008 · Cited by 37
Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01313.x · Cited by 38
Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity
Opinto, G., Natalicchio, A., & Marchetti, P. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.812664 · Cited by 41
Clinical Approaches to Preserve β-Cell Function in Diabetes
WAJCHENBERG, B. L. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_23 · Cited by 38
Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Sakagami, H., Kitsunai, H., Takiyama, Y., Abiko, A., Makino, Y., Kieffer, T. J., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2016.12.009 · Cited by 39
Hydrogen Sulfide and Glucose Homeostasis: A Tale of Sweet and the Stink
Untereiner, A. A., & Wu, L. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7046 · Cited by 40
Kelly, A. T., Sheikh, S., Stefanovski, D., Peleckis, A. J., Nyirjesy, S. C., Eiel, J. N., Sidhaye, A. R., Localio, R., Gallop, R., León, D. D. D., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab365 · Cited by 38
Daousi, C., Pinkney, J. H., Cleator, J., Wilding, J. P. H., & Ranganath, L. R. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.03.004 · Cited by 38
Search for α-helical propensity in the receptor-bound conformation of glucagon-like peptide-1
Murage, E. N., Schroeder, J. C., Beinborn, M., & Ahn, J. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.006 · Cited by 38
BATAILLE, D. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0167-4 · Cited by 39
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
